Ustekinumab: moving the target from psoriasis to Crohn's disease (Q38177321)

30 August 2017

Ustekinumab: moving the target from psoriasis to Crohn's disease (English)

1 reference

30 August 2017

Alessia Settesoldi

1

1 reference

30 August 2017

Manuela Coppola

series ordinal

2

1 reference

30 August 2017

Francesca Rogai

series ordinal

3

1 reference

30 August 2017

Vito Annese

series ordinal

4

1 reference

30 August 2017

25 November 2013

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

8

1 reference

30 August 2017

1

1 reference

30 August 2017

5-13

1 reference

Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Antibodies to watch in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Plasticity of CD4+ T cell lineage differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Antibodies to interleukin 12 abrogate established experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.850414

10.1586/17474124.2014.850414

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference